Related Experiment Videos
Liver transplantation at UCLA: report of clinical activities
D K Imagawa1, S M Strange, A Shaked
1Department of Surgery, UCLA School of Medicine.
Insights
Liver transplantation survival rates exceed 70% at 5 years, with improvements in early post-transplant care. Challenges remain, particularly for infants and organ availability, necessitating donor pool expansion.
Area of Science:
- Hepatology
- Transplant Surgery
- Immunology
Background:
- Liver transplantation is the primary treatment for end-stage liver disease.
- Current 5-year survival rates exceed 70% in most large studies.
- Early post-transplant outcomes significantly impact long-term survival.
Purpose of the Study:
- To review advancements in liver transplantation.
- To highlight challenges in infant transplantation and organ availability.
- To discuss current methods for diagnosing post-transplant complications.
Main Methods:
- Review of existing literature and clinical data on liver transplantation outcomes.
- Analysis of survival rates and factors influencing morbidity and mortality.
- Discussion of diagnostic markers such as AKBR and TNF levels.
- Overview of immunosuppressive agents and clinical trials.
Main Results:
- Significant improvements in 5-year survival rates for liver transplant recipients.
- Higher morbidity and mortality observed in infants compared to older patients.
- Reduced grafts have partially addressed organ shortages, but further expansion is needed.
- AKBR and TNF levels are used to diagnose primary nonfunction and acute rejection.
- Cyclosporine A (CsA) remains the benchmark for immunosuppressive therapy.
Conclusions:
- Liver transplantation offers favorable long-term survival, with ongoing improvements.
- Addressing the organ shortage, especially for pediatric recipients, is critical.
- Postoperative management and diagnostic tools are advancing, with CsA as a standard immunosuppressant.
Abstract:
Liver transplantation remains the treatment of choice for many forms of end-stage liver disease. In most large series, 5-year actuarial survival is greater than 70%. The majority of the morbidity and mortality occurs in the first 6 months posttransplant; as these figures have improved, so have overall survival rates. Infants under 1 year of age have a survival rate below that of older patients; in addition, a severe organ shortage for these patients continues. The use of reduced grafts has ameliorated the problem to a certain extent; however, further expansion of the donor pool is still necessary. Progress has also been made in the postoperative management of transplant patients. We currently follow AKBR and TNF levels in all patients to aid in the diagnosis of primary nonfunction and acute rejection, respectively. The introduction of additional immunosuppressive agents has instigated several large clinical trials. CsA, however, remains the gold standard to which these drugs must be compared.